StonvexLoading…
StonvexStonvexStonvexCore line items from AKAM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $1.12B | $1.07B | $4.21B | $3.11B | $2.06B |
Operating Income | Not available | $114.49M | $566.94M | $472.07M | $306.04M |
Net Income | Not available | $106.32M | $452.03M | $366.96M | $226.79M |
EPS (Diluted) | $1.65 | $0.71 | $3.07 | $2.50 | $1.53 |
Total Assets | Not available | $11.65B | $11.48B | $10.83B | $10.54B |
Total Liabilities | Not available | $6.74B | $6.50B | $6.10B | $6.07B |
Cash & Equivalents | Not available | $622.38M | $930.23M | $927.93M | $850.30M |
Free Cash Flow OCF − CapEx | Not available | $210.82M | $1.01B | $776.09M | $447.04M |
Shares Outstanding | Not available | 145.55M | 144.71M | 143.77M | 143.20M |